Tenglong Tang1,2, Hamzah Abu-Sbeih1, Wenyi Luo3, Phillip Lum1, Wei Qiao4, Robert S Bresalier1, David M Richards1, Yinghong Wang1. 1. a Department of Gastroenterology, Hepatology, and Nutrition , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA. 2. b Department of Minimally Invasive Surgery , The Second Xiangya Hospital of Central South University , Changsha , China. 3. c Division of Pathology and Laboratory Medicine , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA. 4. d Department of Biostatistics , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness in treating many malignancies. Gastrointestinal (GI) adverse events are commonly reported; however, few reports describe upper GI tract toxic effects. We aimed to describe clinical features of upper GI injury related to ICI. Methods: We studied consecutive patients who received ICIs between April 2011 and March 2018 and developed upper GI symptoms requiring esophagogastroduodenoscopy (EGD). Results: Sixty patients developed upper GI symptoms between ICI initiation and 6 months after the last infusion. Among patients who had both EGD and colonoscopy (n = 38), 21 had endoscopic evidence of inflammation involving both the upper and lower GI tract. Overall, histological signs of inflammation of the stomach were evident in 83% of patients, but inflammation of the duodenum in 38%. Total of 42 patients had other risk factors of gastritis, i.e., chemotherapy, radiotherapy, and non-steroidal anti-inflammatory drugs. Only isolated gastric inflammation was seen on endoscopy in patients without these risk factors. The rates of ulceration were similar in the cohorts with and without other risk factors for gastritis. Isolated upper GI inflammation was related to anti-PD-1/L1 in 47% of patients. Immunosuppressive therapy in our cohort with upper GI toxicity consisted of steroids (42%) and infliximab or vedolizumab (23%). Most isolated upper GI symptoms were treated with proton pump inhibitors (65%) or H2 blockers (35%). Conclusion: We observed a correlation between ICI use and onset of upper GI inflammation even when other risk factors were excluded. Gastric involvement was evident more often than duodenal involvement on endoscopic and histological level.
Background: Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness in treating many malignancies. Gastrointestinal (GI) adverse events are commonly reported; however, few reports describe upper GI tract toxic effects. We aimed to describe clinical features of upper GI injury related to ICI. Methods: We studied consecutive patients who received ICIs between April 2011 and March 2018 and developed upper GI symptoms requiring esophagogastroduodenoscopy (EGD). Results: Sixty patients developed upper GI symptoms between ICI initiation and 6 months after the last infusion. Among patients who had both EGD and colonoscopy (n = 38), 21 had endoscopic evidence of inflammation involving both the upper and lower GI tract. Overall, histological signs of inflammation of the stomach were evident in 83% of patients, but inflammation of the duodenum in 38%. Total of 42 patients had other risk factors of gastritis, i.e., chemotherapy, radiotherapy, and non-steroidal anti-inflammatory drugs. Only isolated gastric inflammation was seen on endoscopy in patients without these risk factors. The rates of ulceration were similar in the cohorts with and without other risk factors for gastritis. Isolated upper GI inflammation was related to anti-PD-1/L1 in 47% of patients. Immunosuppressive therapy in our cohort with upper GI toxicity consisted of steroids (42%) and infliximab or vedolizumab (23%). Most isolated upper GI symptoms were treated with proton pump inhibitors (65%) or H2 blockers (35%). Conclusion: We observed a correlation between ICI use and onset of upper GI inflammation even when other risk factors were excluded. Gastric involvement was evident more often than duodenal involvement on endoscopic and histological level.
Authors: Austin R Thomas; Mostafa Eyada; Anusha S Thomas; Yinghong Wang; Miho Kono; Krishnavathana Varatharajalu; Yang Lu; Guofan Xu; Kavea Panneerselvam; Malek Shatila; Mehmet Altan; Jennifer Wang; John A Thompson; Hao Chi Zhang; Muhammad Ali Khan; Gottumukkala S Raju Journal: J Cancer Res Clin Oncol Date: 2022-10-15 Impact factor: 4.322
Authors: Baoqing Chen; Chen Yang; Mihnea P Dragomir; Dongmei Chi; Wenyan Chen; David Horst; George A Calin; Qiaoqiao Li Journal: Ther Adv Med Oncol Date: 2022-07-15 Impact factor: 5.485
Authors: Helene Hjorth Vindum; Jørgen S Agnholt; Anders Winther Moelby Nielsen; Mette Bak Nielsen; Henrik Schmidt Journal: World J Gastroenterol Date: 2020-04-28 Impact factor: 5.742
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751